




FIGURE 1




FIGURE 2

Alignment of h2A2 Heavy Chain Variants with Human Acceptor Sequence, IGHV1-46/HJ4.

	10	20	30	40	50
m2A2 vH					
hIGHV1-46/HJ4	EF..Q...P.LV.....I.....S.D.NVN..K.SN.KS...I.V...KY.T.R.				
h2A2 vHA	QVQLVQSGAEVKPGASVKVSCKASGYTFTSYMHVWRQAPGQGLEWMGIINPSGGSTSY				
h2A2 vHB	.F.....F.....S.D.NVN.....V...KY.T.R.				
h2A2 vHC	.F.....F.....S.D.NVN.....V...KY.T.R.				
h2A2 vHD	.F.....F.....S.D.NVN.....I.V...KY.T.R.				
Kabat CDRs			*****		*****
IMGT CDRs		+++++			+++++

	60	70	80	90	101	110
m2A2 vH						
hIGHV1-46/HJ4	N...K.K.A.L.V.KPS.A.A.Q.N.T...S...T.GLNAW...AS.....					
h2A2 vHA	AQKFQGRVTMTTRDTSTSTVYMELSSLRSEDTAVYYCAR---YFDYWGQGLTVTVSS					
h2A2 vHB	N...K...K...P...T.GLNAW...T.GLNAW...T.GLNAW...T.GLNAW...					
h2A2 vHC	N...K...A.L.V.K...A...T.GLNAW...T.GLNAW...T.GLNAW...					
h2A2 vHD	N...K...A.L.V.KP...A...T.GLNAW...T.GLNAW...T.GLNAW...					
Kabat CDRs	*****				*****	
IMGT CDRs	+++++				+++++	

FIGURE 3




FIGURE 4




FIGURE 5

mAb	EC50 (nM)
m2A2	2
c2A2	3
h2A2 HALB	8
h2A2 HALC	9
h2A2 HALD	12
h2A2 HALE	5
h2A2 HALF	14
h2A2 HALG	1
h2A2 HALH	46
h2A2 HCLB	3
h2A2 HCLC	3
h2A2 HCLD	5
h2A2 HCLE	3
h2A2 HCLF	6
h2A2 HCLG	1
h2A2 HCLH	30

2nM m2A2-AF647 competitor




FIGURE 6






FIGURE 7



mAb	Human aVB6 EC50 (nM)	Cyno aVB6 EC50 (nM)
m2A2-AF647	0.5	0.4
h2A2 HCLG-AF647	0.3	0.2

FIGURE 8



mAb	Human aVB6 EC50 (nM)	Cyno aVB6 EC50 (nM)
h2A2 HCLG	3	3
h2A2 HCLG ADC	4	4

FIGURE 9





FIGURE 10



Cell Line	Cancer Type	QFACS Copy #
HPAFII	Pancreatic	22K
BxPC-3	Pancreatic	37K
Detroit 562	Head & neck	43K
SW780	Bladder	80K

FIGURE 11




FIGURE 12




FIGURE 13




FIGURE 14




FIGURE 15




FIGURE 16




FIGURE 17




FIGURE 18